PP
GLUE icon

Paladin Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Paladin Partners’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.9K Hold
1,000
– – 0.01% 121
2026
Q2 		$24.2K Hold
1,000
– – 0.02% 103
2026
Q1 		$16.4K Hold
1,000
– – 0.01% 115
2025
Q4 		$15.7K Buy
+1,000
New +$13.5K 0.01% 120

Other funds holding GLUE

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Paladin Partners's GLUE Position: Q3 2026 in Review

Paladin Partners held its Monte Rosa Therapeutics (GLUE) position steady in Q3 2026 at 1,000 shares worth $11.9K. The position accounts for 0.01% of the portfolio, ranked #121.

Paladin Partners first reported a position in GLUE in Q4 2025 and has held it in 4 quarters since. The position peaked at $24.2K in Q2 2026. 3 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Paladin Partners held 1,000 shares of Monte Rosa Therapeutics worth $11.9K as of Q3 2026.
  • Paladin Partners left its Monte Rosa Therapeutics share count unchanged in Q3 2026.
  • Monte Rosa Therapeutics made up 0.01% of Paladin Partners's portfolio in Q3 2026, its #121 holding.
  • Paladin Partners first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Paladin Partners's Monte Rosa Therapeutics position peaked at $24.2K in Q2 2026.
  • 3 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Paladin Partners's 13F filing for Q3 2026, filed 6 Oct 2026.